Amgen Sues Roche Over Anemia Treatment

Law360, New York (November 9, 2005, 12:00 AM EST) -- Biotechnology company Amgen Inc., the largest in the world, has filed a lawsuit against three subsidiaries of rival Roche Holding AG, claiming the U.S. patents for its multi-billion dollar anemia treatments are infringed by Roche’s U.S. activities.

Amgen is seeking a declaratory judgment of infringement by Switzerland-based Roche, as well as its subsidiaries F. Hoffmann-LaRoche Ltd., Roche Diagnostics GmbH and Hoffmann-LaRoche Inc. It was filed in the U.S. District Court for the District of Massachusetts.

The treatment in the case, Epogen, is a recombinant version of...
To view the full article, register now.